CN117466992A - 一种纤连蛋白突变体及其制备和应用 - Google Patents
一种纤连蛋白突变体及其制备和应用 Download PDFInfo
- Publication number
- CN117466992A CN117466992A CN202311814537.7A CN202311814537A CN117466992A CN 117466992 A CN117466992 A CN 117466992A CN 202311814537 A CN202311814537 A CN 202311814537A CN 117466992 A CN117466992 A CN 117466992A
- Authority
- CN
- China
- Prior art keywords
- fibronectin
- mutant
- cell
- recombinant
- fibronectin mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 115
- 102000016359 Fibronectins Human genes 0.000 title claims abstract description 115
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000588724 Escherichia coli Species 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000003259 recombinant expression Methods 0.000 claims description 12
- 241000235058 Komagataella pastoris Species 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000021164 cell adhesion Effects 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 230000029663 wound healing Effects 0.000 abstract description 11
- 238000000855 fermentation Methods 0.000 abstract description 10
- 230000004151 fermentation Effects 0.000 abstract description 10
- 230000012292 cell migration Effects 0.000 abstract description 8
- 238000004153 renaturation Methods 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 41
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 35
- 239000008055 phosphate buffer solution Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000001962 electrophoresis Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 102000045742 human FN1 Human genes 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108700010070 Codon Usage Proteins 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001195348 Nusa Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/84—Pichia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311814537.7A CN117466992B (zh) | 2023-12-27 | 一种纤连蛋白突变体及其制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311814537.7A CN117466992B (zh) | 2023-12-27 | 一种纤连蛋白突变体及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117466992A true CN117466992A (zh) | 2024-01-30 |
CN117466992B CN117466992B (zh) | 2024-06-07 |
Family
ID=
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130337038A1 (en) * | 2010-12-14 | 2013-12-19 | University Of Rochester | Chimeric fibronectin matrix mimetics and uses thereof |
CN110511280A (zh) * | 2019-07-16 | 2019-11-29 | 华南理工大学 | 一种透皮重组纤连蛋白及其应用 |
US20210254018A1 (en) * | 2016-07-29 | 2021-08-19 | Takara Bio Inc. | Fibronectin fragment to be used for stem cell production |
CN116640204A (zh) * | 2023-04-14 | 2023-08-25 | 深圳柏垠生物科技有限公司 | 耐热纤连蛋白及其制备方法用途、核酸、表达载体及菌株 |
CN117064821A (zh) * | 2023-10-16 | 2023-11-17 | 宝萃生物科技有限公司 | 一种控油和/或祛痘组合物及其制备和应用 |
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130337038A1 (en) * | 2010-12-14 | 2013-12-19 | University Of Rochester | Chimeric fibronectin matrix mimetics and uses thereof |
US20210254018A1 (en) * | 2016-07-29 | 2021-08-19 | Takara Bio Inc. | Fibronectin fragment to be used for stem cell production |
CN110511280A (zh) * | 2019-07-16 | 2019-11-29 | 华南理工大学 | 一种透皮重组纤连蛋白及其应用 |
CN116640204A (zh) * | 2023-04-14 | 2023-08-25 | 深圳柏垠生物科技有限公司 | 耐热纤连蛋白及其制备方法用途、核酸、表达载体及菌株 |
CN117064821A (zh) * | 2023-10-16 | 2023-11-17 | 宝萃生物科技有限公司 | 一种控油和/或祛痘组合物及其制备和应用 |
Non-Patent Citations (2)
Title |
---|
A SHARMA等: "Crystal structure of a heparin- and integrin-binding segment of human fibronectin", 《THE EMBO JOURNAL》, vol. 18, no. 6, 15 March 1999 (1999-03-15), pages 1468 - 1479 * |
李明才等: "三结构域重组FN多肽表达质粒的构建及其表达产物性质的初步鉴定", 《生物工程学报》, no. 04, 23 July 2000 (2000-07-23), pages 474 - 477 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110845603B (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
WO2017206326A1 (zh) | 一种重组人源胶原蛋白及其编码基因和制备方法 | |
KR20220155565A (ko) | 재조합 인간 xvii형 콜라겐, 제조방법 및 응용 | |
US11780905B2 (en) | Preparation method for collagen hydrogel | |
CN106519042A (zh) | 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因 | |
CN101698682B (zh) | 一种基于抗菌肽的双功能融合蛋白及其制备方法和用途 | |
CN112745394B (zh) | 一种重组类人胶原蛋白及其制备方法和应用 | |
CN115521373B (zh) | 一种三螺旋重组人源化i型胶原蛋白、制备方法及其应用 | |
KR101482187B1 (ko) | 녹색형광단백질―인간상피세포재생인자 융합단백질의 생산을 위한 유전자 컨스트럭트 및 이를 이용한 녹색형광단백질-인간상피세포재생인자 융합단백질의 생산방법 | |
CN114853881B (zh) | 一种重组人源融合胶原蛋白及其高效羟基化方法与应用 | |
CN102747097B (zh) | Ⅰ型人胶原蛋白和表皮生长因子双表达载体及其表达纯化方法 | |
CN116333097A (zh) | 一种高活性的重组人纤连蛋白及其制备方法和应用 | |
CN116535520A (zh) | 一种细胞外基质蛋白融合蛋白及其制备方法和应用 | |
CN111217903A (zh) | 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用 | |
CN111423516B (zh) | 一种蛋白及其在创口修复及抑菌中的应用 | |
CN116574172B (zh) | 重组人源化i型胶原蛋白及其制备方法 | |
CN117466992B (zh) | 一种纤连蛋白突变体及其制备和应用 | |
CN116554309A (zh) | 一种重组人源ⅲ型胶原蛋白及其制备方法和应用 | |
US11639377B2 (en) | Preparation of type I collagen-like fiber and method for regulating and controlling the D-periodic of fiber thereof | |
CN117466992A (zh) | 一种纤连蛋白突变体及其制备和应用 | |
CN106632690A (zh) | 一种重组人热休克蛋白10及其编码基因与制备方法 | |
CN110627889B (zh) | 重组蜘蛛丝蛋白及其制备方法和产业化应用 | |
CN117003889B (zh) | 一种重组热稳定纤连蛋白及其应用 | |
CN115819557B (zh) | 一种三螺旋重组人源化ⅱ型胶原蛋白、制备方法及应用 | |
CN117886922B (zh) | 一种重组人源纤连蛋白及其表达体系 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240513 Address after: Room 502, 5th Floor, Building 20E, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong, China Applicant after: Liankang Biopharmaceutical Co.,Ltd. Country or region after: Hong-Kong Applicant after: Baocui Biotechnology Co.,Ltd. Country or region after: China Address before: 510410 02, 03A, 19 / F, No. 31, No. 31, Jichang Road, Baiyun District, Guangzhou, Guangdong Applicant before: Baocui Biotechnology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant |